Compound ID | 7

Update compound information

MEDI3902

Synonym(s): Gremubamab

Class: Antibody

Agent Type: Direct acting; Indirect acting; Antivirulence; Antibody;
Spectrum of activity: Gram-negative
Mechanism of action: Binds PcrV, inhibiting type III secretion-mediated cytotoxicity, and binds Psl, promoting opsonophagocytic killing and inhibiting bacterial attachment to host cells.
Target Pathogen: Pseudomonas aeruginosa
Description: Bispecific human IgG1κ monoclonal antibody targeting PcrV and Psl of P. aeruginosa.
Institute where first reported: Medimmune, USA
Year first mentioned: 2013
Highest development stage: Phase 2 (NCT04631016)
Development status: Inactive
Reason dropped: Lack of efficacy; primary endpoint not met in the EVADE Phase 2b trial.
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/substance/377483940
Guide to Pharmacology: gremubamab
Citations:
  • https://aac.asm.org/content/63/8/e00710-19
  • https://clinicaltrials.gov/ct2/show/NCT02255760?term=medi3902&rank=1
  • https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-fda-medi3902-nosocomial-pneumonia-prevention-23092014.html#
  • https://www.medimmune.com/research/pipeline
    • Patents:
  • WO2013070615A1
  • WO2014074528A2
  • WO2017095744A1
    		•

    AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.